Skip to main content
BNTX logo

BioNTech SE (BNTX) Stock: Price, Forecast & Analyst Target

BioNTech SE (BNTX) — MoonshotScore 32/100 (Weak band), calculated Nov 18, 2026. Price $83.26 (-1.89%), as of the Nov 18, 2026 trading session; market cap $20.6B.

Educational signal · not a buy or sell recommendation · How to read this

$83.26 −$1.60 (-1.89%) Market Cap $20.6B

BioNTech SE · BNTX · NASDAQ · Healthcare · Biotechnology

BioNTech SE, a biotechnology firm, specializes in the creation and marketing of immune-based treatments for malignancies and various infectious diseases.

Price as of Nov 18, 2026

Key Statistics

32 of 100

MoonshotScore v2 · BioNTech SE (BNTX)

Weak
Business Quality Thin (34)
Financial Safety Okay (40)
Valuation Fair (64)
Growth Durability Shrinking (10)
Momentum Rising (64)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Weak quality and stalling growth, though the balance sheet is only middling. The score also carries a risk penalty for being loss-making and burning cash. Business Quality: Thin; Financial Safety: Okay; Valuation: Fair; Growth Durability: Shrinking; Momentum: Rising.

  • EPS beat 6 of the last 8 reports
  • Altman Z 6.56 · Piotroski F 4
  • ROE -8.1% · ROA -7.4% · current ratio 8.55 · earnings yield -7.6% · free-cash-flow yield -2.4%

Holding back: weak fundamentals, soft growth

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for BNTX (52 recorded, newest six shown)
RecordedScoreBand
34Weak
34Weak
34Weak
34Weak
32Weak
32Weak

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$83.26
Change on the day-1.89%
52-week range$79.52–$124.00
Market capitalisation$20.6B—
Shares traded on the day1.24M
Beta (volatility vs the S&P 500)1.33

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 18, 2026: low $83, high $117, latest $83. $117 $83 high $117 Oct 17, 2025 Nov 18, 2026 · $83 $105Oct 17, 2025$104Oct 31, 2025$103Nov 14, 2025$103Nov 28, 2025$95Dec 12, 2025$95Dec 26, 2025$100Jan 9, 2026$116Jan 23, 2026$107Feb 6, 2026$110Feb 20, 2026$102Mar 6, 2026$89Mar 20, 2026$91Apr 2, 2026$103Apr 17, 2026$98May 1, 2026$90May 15, 2026$96May 29, 2026$91Jun 12, 2026$91Jun 26, 2026$91Jul 10, 2026$89Jul 24, 2026$94Aug 7, 2026$117Aug 21, 2026$104Sep 4, 2026$96Sep 18, 2026$97Oct 2, 2026$88Oct 16, 2026$88Oct 30, 2026$86Nov 13, 2026

Point at or tab to any week for its close.

Other perspectives

Council score for BioNTech SE (BNTX): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Weak
Financial Safety Neutral
Valuation Moderate
Growth Durability Negative
Momentum Moderate

Legends Council

2 lenses, 2 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Unfavorable read

Read on: Nov 20, 2026

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Weak
Margin of Safety Undervalued
Profit Margin Weak
Revenue Growth Weak
Debt/Equity Strong
ROE Negative
Gross Margin Strong

Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Nov 18, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is BioNTech SE (BNTX), and what does it report?

Short answer

BioNTech SE, a biotechnology firm, specializes in the creation and marketing of immune-based treatments for malignancies and various infectious diseases. BioNTech SE (BNTX) is listed on NASDAQ. BioNTech SE (BNTX) is classified as Healthcare / Biotechnology. SEC filing business address: AN DER Goldgrube 12, Mainz, 2M, 55131. It employs 7,807 people and is led by Ugur Sahin. The market values it at $20.6B.

2 · Latest results

What do the latest results show for BioNTech SE (BNTX)?

Short answer · as of

Against analyst estimates the company has EPS beat 6 of the last 8 reports.

Quarterly income statement — 2 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Sep 2025€1.52B-€29M-€0.12 (diluted)
Q4 FY2025€907M-€305M-€1.25 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for BioNTech SE (BNTX)?

Short answer · as of

What is holding it back is weak fundamentals, soft growth. The distress and quality screens read Altman Z 6.56 · Piotroski F 4. Trailing ratios: ROE -8.1% · ROA -7.4% · current ratio 8.55 · earnings yield -7.6% · free-cash-flow yield -2.4%.

4 · What to check next?

What should you watch next at BioNTech SE (BNTX)?

Short answer · as of

Analyst estimates on file carry FY2026 revenue $1.86B · EPS -5.66 · 11 analysts. Current published price targets run low $96.00 · high $140.00 · consensus $118.57 · median $114.00 against a quoted price of $83.26 (as of Nov 18, 2026).

What the records here don't tell us

  • Detailed statement figures are not shown because their conversion to USD has not been verified.
  • The next earnings date is not yet scheduled in the calendar we read.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does BioNTech SE compare with its peers?

Short answer

BioNTech SE's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Exelixis, Inc. (EXEL) Same industry, near in market value$65.83 Nov 19, 2026$16.1B98 5-pillar Nov 18, 2026
United Therapeutics Corporation (UTHR) Same industry, near in market value$577.34 Nov 18, 2026$24.6B97 5-pillar Nov 18, 2026
Ascendis Pharma A/S (ASND) Same industry, near in market value$270.33 Nov 18, 2026$17.7B96 5-pillar Nov 18, 2026
Neurocrine Biosciences, Inc. (NBIX) Same industry, near in market value$162.86 Nov 18, 2026$16.5B95 5-pillar Nov 18, 2026
Halozyme Therapeutics, Inc. (HALO) Same industry, near in market value$93.04 Nov 19, 2026$10.6B95 5-pillar Nov 18, 2026
DexCom, Inc. (DXCM) Named competitor$80.19 Nov 19, 2026$29.9B93 5-pillar Nov 18, 2026
Bio-Techne Corporation (TECH) Same industry, near in market value$72.70 Nov 19, 2026$11.4B92 5-pillar Nov 18, 2026
Incyte Corporation (INCY) Same industry, near in market value$117.80 Nov 18, 2026$24.0B91 5-pillar Nov 18, 2026
Koninklijke Philips N.V. (PHG) Named competitor$29.27 Nov 19, 2026$28.6B78 5-pillar Nov 18, 2026
Royalty Pharma plc (RPRX) Same industry, near in market value$68.67 Nov 18, 2026$39.5B73 5-pillar Nov 18, 2026
Alnylam Pharmaceuticals, Inc. (ALNY) Same industry, near in market value$149.40 Nov 18, 2026$20.0B72 5-pillar Nov 18, 2026
Genmab A/S (GMAB) Same industry, near in market value$50.97 Nov 18, 2026$31.4B72 5-pillar Nov 18, 2026
BioNTech SE (BNTX) — this page$83.26$20.6B32

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$96.00 – $140.00
Consensus target
$118.57
Median target
$114.00
Revenue estimate
$1.86B
EPS estimate
$-5.66

Consensus record · Captured .

Measured against a quoted price of $83.26 (as of Nov 18, 2026).

Insider activity

Form 4 records via FMP · Of the newest 500 records, those within the last 180 days, newest dated Oct 9, 2026

Transactions
26
Identified insiders
1
Purchases
0
Sales
26
Other transactions
0

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held BNTX in their latest 13F filing, and what they did against the filing before it.

InvestorManager13F quarterPortfolio weightValueLast quarter
ARK InvestCathie WoodQ3 20260.00%$237.00Trimmed −100.0% shares

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about BioNTech SE (BNTX)?

Read these with our analysis →

Common Questions About BNTX (Healthcare)

These answers are editorial: 1 of these 9 answers is drawn from the BNTX research dossier (written Jun 14, 2026 by gpt-4o-mini); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.

What does the MoonshotScore mean for BNTX?

BNTX carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.

Is BNTX a good stock to buy?

Stock Expert AI does not rate BNTX buy, sell or hold. BioNTech SE carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the BNTX stock price today?

The last price recorded for BioNTech SE (BNTX), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the BNTX price target?

The analyst consensus price target for BioNTech SE (BNTX), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

What do analysts say about BNTX stock?

Analysts generally view BioNTech SE as a key player in the biotechnology sector, particularly due to its innovative mRNA technology and strong pipeline.

What are the key factors to evaluate for BNTX?

BioNTech SE (BNTX) holds a MoonshotScore in the low range. To weigh it, read the analyst view under Analyst targets & estimates on this page. No dividend yield as the company reinvests profits into R&D for future growth. Not financial advice.

How frequently does BNTX data refresh on this page?

BNTX's price is the last quote we recorded, from the Nov 18, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven BNTX's recent stock price performance?

BioNTech SE (BNTX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative mRNA technology with proven efficacy in vaccines. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider BNTX overvalued or undervalued right now?

BioNTech SE (BNTX) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Its analyst consensus target is listed under Analyst targets & estimates on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 25 figures on this page — 1 from SEC filings and earnings calls, 15 from Financial Modeling Prep (FMP), 7 with no recorded source and 2 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.

ETFs that hold BNTX

Funds in our ETF coverage that list BNTX among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.

ETFWeightHoldings as of
iShares Genomics Immunology and Healthcare ETF (IDNA)3.89%
Global X - Genomics & Biotechnology ETF (GNOM)3.87%
WisdomTree BioRevolution Fund (WDNA)2.41%